Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

To compare the magnitude of celecoxib versus rofecoxib on the cardiovascular risk. We performed adjusted indirect comparison of celecoxib versus rofecoxib for cardiovascular events using two data on The Adenomatous Polyp Prevention on Vioxx (APPROVe) trial and Adenoma Prevention with Celecoxib (APC) trial. Baseline characteristics of the patients and placebos were comparable in both trials, in terms of age, sex, hypertension, diabetes mellitus, smoking, and hypercholesterolemia. The overall incidence of cardiovascular events was similar in both groups (rofecoxib 48/1,287 versus celecoxib 48/1,356, p = 0.79). The relative risks (RRs) of all myocardial infarction or sudden death from cardiac causes were increased in both rofecoxib and celecoxib groups [rofecoxib versus placebo; RR 1.35, 95% confidence interval (CI) 1.07-1.69, p = 0.03, celecoxib versus placebo; RR 1.35, 95% CI 1.14-1.51, p = 0.01]. The RRs for cardiovascular events derived from the adjusted indirect comparisons of the two coxibs did not significantly differ from unity (celecoxib versus rofecoxib; RR 0.95, 95% CI 0.76-1.19, p = 0.67). The adjusted indirect comparison analysis shows that celecoxib and rofecoxib may have similarly effect of cardiovascular events when used for 3 years.

Original languageEnglish
Pages (from-to)477-482
Number of pages6
JournalRheumatology International
Volume27
Issue number5
DOIs
Publication statusPublished - 2007 Mar 1

Fingerprint

Celecoxib
Placebos
Confidence Intervals
Adenomatous Polyps
rofecoxib
Cyclooxygenase 2 Inhibitors
Sudden Cardiac Death
Hypercholesterolemia
Adenoma

Keywords

  • Adjusted indirect comparison
  • Cardiovascular risk
  • COXIBS

ASJC Scopus subject areas

  • Rheumatology

Cite this

Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk. / Lee, Young Ho; Ji, Jong Dae; Song, Gwan Gyu.

In: Rheumatology International, Vol. 27, No. 5, 01.03.2007, p. 477-482.

Research output: Contribution to journalArticle

@article{b65cd37d227a48efbb259570016da302,
title = "Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk",
abstract = "To compare the magnitude of celecoxib versus rofecoxib on the cardiovascular risk. We performed adjusted indirect comparison of celecoxib versus rofecoxib for cardiovascular events using two data on The Adenomatous Polyp Prevention on Vioxx (APPROVe) trial and Adenoma Prevention with Celecoxib (APC) trial. Baseline characteristics of the patients and placebos were comparable in both trials, in terms of age, sex, hypertension, diabetes mellitus, smoking, and hypercholesterolemia. The overall incidence of cardiovascular events was similar in both groups (rofecoxib 48/1,287 versus celecoxib 48/1,356, p = 0.79). The relative risks (RRs) of all myocardial infarction or sudden death from cardiac causes were increased in both rofecoxib and celecoxib groups [rofecoxib versus placebo; RR 1.35, 95{\%} confidence interval (CI) 1.07-1.69, p = 0.03, celecoxib versus placebo; RR 1.35, 95{\%} CI 1.14-1.51, p = 0.01]. The RRs for cardiovascular events derived from the adjusted indirect comparisons of the two coxibs did not significantly differ from unity (celecoxib versus rofecoxib; RR 0.95, 95{\%} CI 0.76-1.19, p = 0.67). The adjusted indirect comparison analysis shows that celecoxib and rofecoxib may have similarly effect of cardiovascular events when used for 3 years.",
keywords = "Adjusted indirect comparison, Cardiovascular risk, COXIBS",
author = "Lee, {Young Ho} and Ji, {Jong Dae} and Song, {Gwan Gyu}",
year = "2007",
month = "3",
day = "1",
doi = "10.1007/s00296-006-0244-y",
language = "English",
volume = "27",
pages = "477--482",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk

AU - Lee, Young Ho

AU - Ji, Jong Dae

AU - Song, Gwan Gyu

PY - 2007/3/1

Y1 - 2007/3/1

N2 - To compare the magnitude of celecoxib versus rofecoxib on the cardiovascular risk. We performed adjusted indirect comparison of celecoxib versus rofecoxib for cardiovascular events using two data on The Adenomatous Polyp Prevention on Vioxx (APPROVe) trial and Adenoma Prevention with Celecoxib (APC) trial. Baseline characteristics of the patients and placebos were comparable in both trials, in terms of age, sex, hypertension, diabetes mellitus, smoking, and hypercholesterolemia. The overall incidence of cardiovascular events was similar in both groups (rofecoxib 48/1,287 versus celecoxib 48/1,356, p = 0.79). The relative risks (RRs) of all myocardial infarction or sudden death from cardiac causes were increased in both rofecoxib and celecoxib groups [rofecoxib versus placebo; RR 1.35, 95% confidence interval (CI) 1.07-1.69, p = 0.03, celecoxib versus placebo; RR 1.35, 95% CI 1.14-1.51, p = 0.01]. The RRs for cardiovascular events derived from the adjusted indirect comparisons of the two coxibs did not significantly differ from unity (celecoxib versus rofecoxib; RR 0.95, 95% CI 0.76-1.19, p = 0.67). The adjusted indirect comparison analysis shows that celecoxib and rofecoxib may have similarly effect of cardiovascular events when used for 3 years.

AB - To compare the magnitude of celecoxib versus rofecoxib on the cardiovascular risk. We performed adjusted indirect comparison of celecoxib versus rofecoxib for cardiovascular events using two data on The Adenomatous Polyp Prevention on Vioxx (APPROVe) trial and Adenoma Prevention with Celecoxib (APC) trial. Baseline characteristics of the patients and placebos were comparable in both trials, in terms of age, sex, hypertension, diabetes mellitus, smoking, and hypercholesterolemia. The overall incidence of cardiovascular events was similar in both groups (rofecoxib 48/1,287 versus celecoxib 48/1,356, p = 0.79). The relative risks (RRs) of all myocardial infarction or sudden death from cardiac causes were increased in both rofecoxib and celecoxib groups [rofecoxib versus placebo; RR 1.35, 95% confidence interval (CI) 1.07-1.69, p = 0.03, celecoxib versus placebo; RR 1.35, 95% CI 1.14-1.51, p = 0.01]. The RRs for cardiovascular events derived from the adjusted indirect comparisons of the two coxibs did not significantly differ from unity (celecoxib versus rofecoxib; RR 0.95, 95% CI 0.76-1.19, p = 0.67). The adjusted indirect comparison analysis shows that celecoxib and rofecoxib may have similarly effect of cardiovascular events when used for 3 years.

KW - Adjusted indirect comparison

KW - Cardiovascular risk

KW - COXIBS

UR - http://www.scopus.com/inward/record.url?scp=33847140532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847140532&partnerID=8YFLogxK

U2 - 10.1007/s00296-006-0244-y

DO - 10.1007/s00296-006-0244-y

M3 - Article

VL - 27

SP - 477

EP - 482

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 5

ER -